OTC · Biotechnology

Ascletis Pharma Inc. (ASCLF) Stock

$1.42 +0.00% OTC: ASCLF Healthcare

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus.

Valuation

MetricValue
Price$1.42
Market Cap$1.49B
P/E Ratio-20.87
P/B Ratio3.93
P/S Ratio4014.88
EPS (TTM)$-0.36
52-Week High$2.50
52-Week Low$1.15
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-18.93%
ROA-17.41%
ROCE-24.94%
Gross Margin25.99%
Operating Margin-23550.00%
Net Margin-17550.00%
Debt/Equity0.00
Current Ratio15.05

Annual Financials (USD)

Metric20212022202320242025
Revenue$77.0M$54.0M$57.0M$1.0M$2.0M
Operating Profit$-225.0M$-344.0M$-300.0M$-295.0M$-471.0M
Net Profit$-199.0M$-315.0M$-145.0M$-301.0M$-351.0M
EPS$-0.18$-0.29$-0.13$-0.30$-0.36
Op Margin-292.6%-635.9%-530.4%-23025.6%-23854.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.8B$2.7B$2.5B$2.1B$2.1B
Total Liabilities$101.0M$117.0M$149.0M$158.0M$130.0M
Cash$2.5B$2.5B$330.0M$866.0M$1.4B
Borrowings$3.0M$4.0M$8.0M$8.0M$5.0M

Latest News

Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting PR Newswire · Jul 23, 2026 Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30 PR Newswire · Jul 15, 2026 Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35 PR Newswire · Jul 6, 2026 Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35 PR Newswire · Jul 6, 2026 Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity PR Newswire · Jun 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-147.0M$-142.0M$-144.0M$-342.0M$-329.0M
Investing Cash Flow$-282.0M$-1.3B$131.0M$977.0M$564.0M
Financing Cash Flow$-29.0M$0$-79.0M$-99.0M$-86.0M
Net Cash Flow$-483.0M$-1.3B$-74.0M$534.0M$613.0M
Free Cash Flow$-154.0M$-157.0M$-163.0M$-344.0M$-331.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.60
EV / EBITDA-14.21
FCF Yield-4.66%
Quick Ratio15.04
Interest Coverage-5674.85
Return 1Y2.90%
Return 3Y632.34%
Return 5Y—

Ownership

Insiders Held65.76%
Institutions Held12.73%
Institutions Float Held37.18%
Institutional HolderSharesReport Date
iShares, Inc.-iShares Core MSCI Emerging Markets ETF2,352,0002026-06-30
Roundhill ETF Trust-Roundhill GLP-1 & Weight Loss ETF1,133,0002026-03-31
SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Emerging Markets ETF714,0002026-06-30
AB CAP FUND, INC.-AB All China Equity Portfolio203,0002026-05-31
Invesco Exch-Trd Fd. TRT II-Invesco Intl BuyBack Achievers ETF191,1052026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BIOGYBioGaia AB (publ) $11.00 +0.00% 33.70 $1.11B 3.82%
CSPHFCStone Pharmaceuticals $0.71 +0.00% -19.48 $1.14B 0.00%
IDRSFIdorsia Ltd $8.00 +0.00% -4.74 $2.04B 0.00%
INRLFValneva SE $2.43 -7.25% -2.67 $460.84M 0.00%
LJUIFSSY Group Limited $0.40 +0.00% 14.97 $1.19B 2.50%

About Ascletis Pharma Inc.

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.

Ascletis Pharma Inc. is headquartered in CN.

Ascletis Pharma Inc. (ASCLF) stock trades at $1.42 with a market capitalization of $1.49B. The stock is valued at a price-to-earnings (P/E) ratio of -20.87, price-to-book of 3.93, price-to-sales of 4014.88. Over the past 52 weeks the stock has ranged between $1.15 and $2.50, and currently trades 43.2% below its 52-week high.

On profitability, Ascletis Pharma Inc. generates a return on equity (ROE) of -18.93%, return on capital employed of -24.94%, an operating margin of -23550.00%, a net profit margin of -17550.00%.

Official website: www.ascletis.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides